GLP-1
Shop GLP-1Also called: GLP-1 peptide, MDWK-712 (AI-Optimized GLP-1), LAE102 and GLP-1 treatment
GLP-1 is a tiny natural body chemical that helps control hunger. Drugs made like it are often given as a weekly or daily shot. Many people use them to lose weight and to help control blood sugar. GLP-1 drugs work by making you feel full sooner and by calming your appetite.
Your stomach empties more slowly, so you eat much less food. Studies show this can lead to big weight loss for many people. Because you eat less, choosing foods with lots of protein and fiber matters a lot. It helps protect your muscles while the weight comes off.
Not everything about these drugs is settled. Some people feel sick or get an upset stomach, especially at first. The weight can come back if you stop taking the drug, so long-term plans matter. Only take it with a real doctor's care, and avoid buying it from unapproved sellers, which can be unsafe.
Benefits
What GLP-1 Helps With
The main themes across 304 research studies, in plain language.
Glycemic & metabolic
Blood sugar regulation
95/100Rated 95/100Source typePeer-reviewed studyIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 96 underlying claimsResearch suggests these mechanisms help stabilize blood sugar levels by enhancing insulin secretion and sensitivity in response to glucose.
Drug formulation & stability
72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 51 underlying claimsResearch focuses on extending the stability and half-life of therapeutic peptides for improved delivery.
Pancreatic beta-cell health
90/100Rated 90/100Source typePeer-reviewed studyIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 42 underlying claimsLaboratory studies suggest these compounds may help preserve insulin-producing cells in the pancreas and reduce cellular stress.
Neuroprotection & cognitive
Neuroprotection & cognition
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 27 underlying claimsEvidence suggests potential benefits for brain health, including protection against inflammation, plaque buildup, and cognitive decline.
Addiction & reward modulation
90/100Rated 90/100Source typePeer-reviewed studyIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 10 underlying claimsPreliminary research suggests potential to dampen brain reward pathways associated with cravings for substances like nicotine and alcohol.
Renal & hepatic
Liver health & metabolism
60/100Rated 60/100Source typeSpecialist communityIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 15 underlying claimsEvidence points to potential benefits for liver metabolism, including the reduction of fat accumulation and improved lipid profiles.
Kidney function support
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 8 underlying claimsStudies indicate potential to support kidney health and reduce the risk of disease progression.
Musculoskeletal support
60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 9 underlying claimsResearch suggests potential roles in supporting bone density, joint health, and muscle function.
Research examples
- Sitagliptin modestly preserves or increases bone mineral density without adverse bone quality changes
- GLP-1RAs reduce osteoarthritis pain and slow cartilage loss
- GLP-1 improves muscle endurance via microvascular recruitment
Gastrointestinal motility
95/100Rated 95/100Source typePeer-reviewed studyIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 24 underlying claimsResearch suggests a role in slowing the emptying of the stomach and regulating gut movement.
Research examples
- Decrease of gastric emptying
- Slowed gastric emptying
- Inhibition of gastric emptying and intestinal motility
Anti-inflammatory effects
90/100Rated 90/100Source typePeer-reviewed studyIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 18 underlying claimsResearch indicates the ability to lower inflammatory markers and modulate immune responses in various tissues.
Cellular defense & survival
90/100Rated 90/100Source typePeer-reviewed studyIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 18 underlying claimsStudies suggest mechanisms that protect cells from stress, damage, and programmed cell death.
Weight management & appetite
95/100Rated 95/100Source typePeer-reviewed studyIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 86 underlying claimsStudies indicate effects on reducing appetite, slowing digestion, and decreasing food intake to support weight loss.
Cardiovascular protection
90/100Rated 90/100Source typePeer-reviewed studyIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 28 underlying claimsResearch points to protective effects on the heart and blood vessels, including improved function and reduced risk of major adverse events.
Sleep & breathing disorders
50/100Rated 50/100Source typeUnclassified sourceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 underlying claimsEmerging clinical evidence is exploring potential benefits for conditions like obstructive sleep apnea.
Free: The Peptide Stack Cheat-Sheet
You just read the research on GLP-1. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
How People Use It
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
- Oral solid dosage form (tablet core or minitablet with immediate release coating) 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Honest expectations
What GLP-1 doesn’t do
What the sourced research says it doesn’t do — as notable as what it does.
- Lowers meal-related glycemic excursion in Type 2 diabetes without increasing insulin 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↵ source
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- VomittingMild 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ macmillan.princeton.edu
- GI side effectsMild 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ macmillan.princeton.edu
- Lowered blood glucose levelsModerate 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
- Partial beta-cell lossSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
- Moderate hyperglycemiaModerate 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
- Reduced thirstMild 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ health.osu.edu
- FaintingSevereReported in 2 sources 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ health.osu.edu↗ news-medical.net
- FallsSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ health.osu.edu
- OverdoseSevere 80/100Rated 80/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ kumc.edu
- Acute pancreatitisModerate 75/100Rated 75/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org
- Loss of lean muscle massModerate 75/100Rated 75/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ kumc.edu
- Kidney problemsSevere 75/100Rated 75/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medicare.chir.georgetown.edu
- Pancreas problemsSevere 75/100Rated 75/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medicare.chir.georgetown.edu
- Gastrointestinal problemsModerate 75/100Rated 75/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medicare.chir.georgetown.edu
- Cibenzoline-induced hypoglycemiaSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ springermedicine.com
- Immune checkpoint inhibitor-related hypophysitisSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ springermedicine.com
- Risks of side effects from frequent dosing of short half-life drugsModerate 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ patents.google.com
- HypoglycemiaModerateReported in 3 sources 70/100Rated 70/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ patents.google.com↗ poisonhelp.org↗ elliemd.com
- VomitingMildReported in 13 sources 70/100Rated 70/100Source typeEstablished referenceIndependent sources13Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ health.osu.edu↗ patents.google.com↗ health.yahoo.com↗ blog.profil.com+9
- NauseaMildReported in 30 sources 70/100Rated 70/100Source typeEstablished referenceIndependent sources30Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ health.osu.edu↗ macmillan.princeton.edu↗ patents.google.com↗ glucagon.com+26
- Nutritional deficienciesModerate 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pharmaphorum.com
- Potential risk of pancreatic cancerSevere 60/100Rated 60/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org
- Attenuated insulin secretion following test meal ingestionMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Weight lossMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Increased muscle sympathetic nerve activityMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Acute hypothermiaModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Compensatory reduction in energy expenditureMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Significant weight loss (>10%) during chemotherapyModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Increased number of intestinal polypsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Decreased bone mineral density and quality following ovariectomyModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Rapid tachyphylaxis of GLP-1-induced deceleration of gastric emptyingModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Reduction in TSH levelsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Thyroid C-cell activation and proliferationModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Increased heart rateMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Hypoglycemia in fasted healthy subjectsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Reactive hypoglycemia post-gastrectomy and post-gastric bypassModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Reactive hypoglycemia in children after Nissen fundoplicationModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Hypoglycemia when combined with sulfonylurea agentsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Reactive hypoglycemia from neuroendocrine tumor secreting GLP-1Severe 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Gastrointestinal adverse eventsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Gastrointestinal side effectsModerateReported in 4 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com↗ blog.profil.com↗ elliemd.com↗ seekpeptides.com
- Hypoglycemia (comparatively less with GLP-1 vs standard therapy)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Rare allergic reactions including mild anaphylaxisSevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Peritracheal edema following captopril administration in DPP-4 deficient ratsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Inflammation-associated paw edema potentiated by DPP-4 inhibitionModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Enhanced severity of experimental inflammation in CD26-/- miceModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Pioglitazone reduced bone mineral density and bone qualityModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Pioglitazone caused significant weight gain and fat accumulationMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Hyperinsulinemic hypoglycemiaSevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Nesidioblastosis (islet hyperplasia)Severe 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- InsulinomaSevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Dumping syndromeModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- NeuroglycopeniaSevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get GLP-1
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Timeline
History & Milestones
Key moments in GLP-1’s research and regulatory timeline — sourced and dated.
News
Latest on GLP-1
Dated, sourced reporting that mentions GLP-1.
Semaglutide’s heart benefits may extend beyond weight loss
New research suggests semaglutide's cardiovascular benefits may occur partly independently of its weight-loss effects. The GLP-1 receptor agonist, known for treating type 2 diabetes and obesity, appears to improve heart health through additional mechanisms. This may broaden its potential use in patients with cardiovascular disease.
CagriSema bests tirzepatide for weight loss in type 2 diabetes
Novo Nordisk announced topline results showing CagriSema, a fixed-dose combination of cagrilintide and semaglutide, produced greater weight loss than tirzepatide in adults with type 2 diabetes in the REIMAGINE 5 trial (12.4% vs. 9.1% at 60 weeks), while achieving noninferior HbA1c reductions. In the REDEFINE 9 trial, CagriSema led to 21% weight loss at 68 weeks in adults with overweight or obesity without diabetes. These are topline company-announced results from ongoing trial programs.
Wegovy benefits consistent regardless of frailty level
A new analysis of the SELECT trial published in JAMA Cardiology found that semaglutide 2.4 mg (Wegovy) delivered cardiovascular benefits versus placebo consistently across all frailty levels. The most frail patients experienced the greatest quality-of-life improvements. The findings address concerns that GLP-1 therapies may be less safe or effective in frail populations.
Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected
A comparative study evaluated tirzepatide and semaglutide for asthma outcomes, finding the difference between the two GLP-1-based drugs was smaller than anticipated. Both peptides showed potential benefits in asthma control, likely linked to weight loss and anti-inflammatory effects. The findings suggest either drug may help patients with obesity-related asthma.
Semaglutide linked to fewer exacerbations in asthma, COPD
An abstract presented at the 2026 European Respiratory Society International Congress links semaglutide use in patients with type 2 diabetes to fewer exacerbations in asthma (38% reduction) and COPD (21% reduction). Other GLP-1 receptor agonists like exenatide and dulaglutide also showed exacerbation reductions. The associations persisted regardless of weight or glycemic changes, suggesting possible direct lung anti-inflammatory effects.
Wondering how GLP-1 pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →